Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.

Learn More
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH
Back To Doctor Search

Fern M. Anari, MD

Specialties

Genitourinary Medical Oncology

Loading ...
About Me
Offices
Publications
Ratings & Reviews
About Me
  • Philadelphia Magazine Top Doctors, 2023-24
  • American Medical Women's Association Glasgow-Rubin Citation for Academic Achievement, 2013
  • Angelo P. Angelides Award for Academic Excellence in Medicine, 2013

 

Offices

Office Locations

Fox Chase Cancer Center

333 Cottman Avenue

Philadelphia, PA 19111

Phone: 888-369-2427

Fox Chase - East Norriton

2701 Dekalb Pike

East Norriton, PA 19401

Phone: 888-369-2427

Publications
Publications
  • Winer A, Ghatalia P, Bubes N, Anari F, Varshavsky A, Kasireddy V, Liu Y, El-Deiry WS. Dual checkpoint inhibition with ipilimumab plus nivolumab after progression on sequential PD-1/PDL-1 inhibitors pembrolizumab and atezolizumab in a patient with Lynch Syndrome, metastatic colon and localized urothelial cancer. The Oncologist.
  • Ghatalia P, Smith CH, Winer A, Gou J, Kiedrowski LA, Saltzberg PD, Bubes N, Anari F, Kasireddy V, Varshavsky A, Liu Y, Ross E, El-Deiry WS. Clinical use of liquid biopsies to detect actionable driver mutations, guide treatment decisions and monitor disease burden during treatment of 33 metastatic colorectal cancer patients at Fox Chase Cancer Center GI Oncology subspecialty clinic. Frontiers in Oncology. 2019 Jan, 8(1-8).    
  • Anari F, Dotan E. Management of Older Adults with Colorectal Cancer. Hospital Physician Hematology/Oncology Board Review Manual. 2018,13(4):7-22. 
  • Anari F, Ramamurthy C, Zibelman M. Impact of Tumor Microenvironment Composition on Therapeutic Responses and Clinical Outcomes in cancer. Future Oncology. 2018 Jun;14(14):1409-1421.
  • Anari F, O’Neill J, Choi W, Chen D, Haseebuddin M, Kutikov A, Dulaimi E, Alpaugh RK, Devarajan K, Greenberg R, Bilusic M, Wong YN, Viterbo R, Hoffman-Censits JH, Lallas C, Trabulsi E, Smaldone M, Geynisman D, Zibelman M, Lin J, Kelly WK, Uzzo R, McConkey D, Plimack ER. Neoadjuvant Dose-Dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial. European Urology Oncology. 2018 May;1(1):54-60.
Ratings & Reviews

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient Comments

Loading ...